TY - JOUR
T1 - Chronic calcium antagonist use in carcinoma of the lung and colon
T2 - A retrospective cohort observational study
AU - Zacharski, Leo R.
AU - Moritz, Thomas E.
AU - Haakenson, Clair M.
AU - O'Donnell, Joseph F.
AU - Ballard, Harold S.
AU - Johnson, Gerhard J.
AU - Ringenberg, Q. Scott
AU - Schilsky, Richard L.
AU - Spaulding, Monica B.
AU - Tornyos, Karl
AU - Williams, Charles C.
PY - 1990
Y1 - 1990
N2 - Detailed records were maintained prospectively of all medications taken by 719 patients with advanced carcinoma of the lung or colon. Of this total, a cohort of 19 patients was identified who had ingested incidentally either nifedipine, diltiazem, verapamil, or trifluoperazine in standard therapeutic doses for a minimum of one month and a mean of 5.8 months and median of three months. Treatment with these calcium antagonists was well tolerated and, upon comparison with otherwise comparable patients who did not ingest a calcium antagonist, appeared to be associated with certain favorable outcomes, including delayed tumor progression and prolonged survival. These preliminary findings suggest that beneficial effects of such drugs observed with chronic treatment in experimental animal tumor models may occur in human disease and that definitive prospective, randomized, clinical trials of calcium antagonists administered continuously in ordinary therapeutic doses are both feasible and justified.
AB - Detailed records were maintained prospectively of all medications taken by 719 patients with advanced carcinoma of the lung or colon. Of this total, a cohort of 19 patients was identified who had ingested incidentally either nifedipine, diltiazem, verapamil, or trifluoperazine in standard therapeutic doses for a minimum of one month and a mean of 5.8 months and median of three months. Treatment with these calcium antagonists was well tolerated and, upon comparison with otherwise comparable patients who did not ingest a calcium antagonist, appeared to be associated with certain favorable outcomes, including delayed tumor progression and prolonged survival. These preliminary findings suggest that beneficial effects of such drugs observed with chronic treatment in experimental animal tumor models may occur in human disease and that definitive prospective, randomized, clinical trials of calcium antagonists administered continuously in ordinary therapeutic doses are both feasible and justified.
UR - http://www.scopus.com/inward/record.url?scp=0025684765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025684765&partnerID=8YFLogxK
U2 - 10.3109/07357909009012067
DO - 10.3109/07357909009012067
M3 - Article
C2 - 2176124
AN - SCOPUS:0025684765
SN - 0735-7907
VL - 8
SP - 451
EP - 458
JO - Cancer Investigation
JF - Cancer Investigation
IS - 5
ER -
